Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 14, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions

Peripheral Artery DiseasePeripheral Vascular DiseasesPeripheral Arterial DiseasePeripheral Arterial Occlusive Disease

Interventions

DRUG

Vumerity

diroximal fumarate 462 mg (2 capsules)

OTHER

Placebo

Microcrystalline cellulose 462 mg (2 capsules)

Trial Locations (1)

RECRUITING

University of Nebraska - Omaha, Omaha

All Listed Sponsors

lead

University of Nebraska

OTHER